

Fast Facts about IMI's European Lead Factory

- Aim: To provide quality lead compounds for innovative disease-related targets
- IMI funding term: 2013-2017
- Total budget: 196 M€, i.e. 80 M€ (IMI) + 91 M€ (EFPIA in-kind) + 25 M€ (public participants)
- 30 participants = 13 academic + 10 SMEs + 7 EFPIA
- 150 public partner employees involved
- Any researcher at any European SME or academic institute can take part as target owners or chemical library designers
- Researchers in 13 countries (BE, DE, DK, ES, FR, IT, IL, HU, NL, PL, PT, SE, UK) involved, so far. Partners spread over 8 countries and target owners over 11.

Results, as of 11 October 2016

- A Sweden-based start-up company, ScandiCure AB, has been founded based on the results of an ELF target programme. ScandiCure is developed with the support and investment of GU Ventures, which is wholly owned by the Swedish State.
- Patents on ELF compounds for treatment of multi-resistant bacteria infections and cancer.
- An ELF programme accepted by IMI's ENABLE for preclinical development.
- *In vivo* proof-of-concept generated with ELF compounds.
- 2 PhD thesis enhanced with ELF target programme assay development and screening results.
- >40 scientific, peer-reviewed articles, whereof one is the 4th most downloaded article published in Drug Discovery Today in 2015.
- 460,000 compounds in the Joint European Compound Library (JECL), whereof ~130,000 of the prospected 200,000 novel screening compounds have been synthesised. 330,000 compounds were selected and assembled from the EFPIA participants' proprietary compound within the first 6 months of operation giving the screening operations a flying start.
- Many testimonials of the high quality of the ELF output and the JECL compounds. For example, 17/49 EFPIA partner screens have triggered further work.
- 73 public target programmes accepted, 49 high throughput screens finished and 43 hit lists with associated data reports handed over to the target owners.
- In total, 3183 qualified hits have been granted public and private target owners (1143 and 2040, respectively).
- >1500 bespoke compounds synthesised in hit validation and hit-to-lead phase of public target programmes. >10 crystals structures of target-compound complexes have been solved.
- >150 bespoke assays have been developed in order to extract the most interesting hits for public programmes.
- 12/14 of the public target programmes offered to the EFPIA have been asked to provide a dossier for further assessment.
- >60 academic postdoctoral fellows trained in industry methods and approaches.
- 2 Custom-built data management platforms, the Honest Data Broker system developed to enable screening data management and triaging, whilst ensuring confidentiality and patentability; TarosGate2, a chemistry workflow management system with a secure built-in electronic laboratory notebook.

More details and news can be found on www.europeanleadfactory.eu